The Kelman™ Quadraflex™* anterior chamber lens from CILCO.™



The Kelman™ Quadraflex™ anterior chamber lens is designed by Charles D. Kelman, M.D. and is lathe cut in a single piece from Perspex® CQ polymethylmethacrylate.

Diameter of the optic is 5.0 mm. The full range of diopter powers is available. Width of the superior footplate is 5.0 mm. Width of the inferior footplate is 6.0 mm. Sizes (overall diagonal length) range from 11.5 mm to 13.5 mm in 0.5 mm increments.

Videotape on implantation of the Kelman Quadraflex lens is available for loan from CILCO's United Kingdom office. Write or telephone for further information.

CILCO™

U.K., Ireland and Scandinavia:
CILCO, Inc., 3 Waterdene House
Water Lane, Leighton Buzzard
Bedfordshire, England LU77AW
Telephone: (0525) 381122
TLX: 848 507

Europe, Middle East and Africa:
CILCO SARL, 99 rue Georges
Clemenceau, Cannes, France 06400
Telephone: (93) 38 06 99
TLX: 470 900

Canada: CILCO Canada, Simcoe Building
Suite 206, 345 Kingston Road
Pickering, Ontario L1V1A1
Telephone: 416/286-1416

U.S.A.: CILCO, Inc., 1616 13th Avenue
Box 1680, Huntington WV 25717
Telephone: 304/697-4422
TLX: 886-453

U.S. Patent no. 4,174,543

AN IMPORTA
IN THE TR
OF HERPES SIMP

ZOVIRAX is a highly selective antiherpes agent with a fundamentally different mode of action, and extremely low toxicity.

● Unique mode of action
A Wellcome discovery, ZOVIRAX is the first antiherpes agent that is activated to any significant extent only when the herpes simplex virus is present. ZOVIRAX is converted to a monophosphate form by a herpes-specific thymidine kinase enzyme. This starts a chain of events resulting in the active compound, the triphosphate form, which inhibits viral replication. In chemically signalling its presence the virus thus seals its own fate.

● Highly effective with rapid action
In clinical studies ZOVIRAX has been shown to be superior to idoxuridine.[1] In the trial, healing time was quicker with ZOVIRAX.

Antiviral activity has been well demonstrated in *in vitro* studies. ZOVIRAX ".. was found to be between 5 and 10 times more active than cytarabine, idoxuridine and trifluorothymidine, and more than 100 times more active than vidarabine."[2]

● Greater selectivity
Because of its unique mode of action, ZOVIRAX can be regarded as an ultra-selective agent. Once "bioactivated" it has a 10 to 30-fold greater affinity for viral DNA polymerase than for cellular polymerase. In tissue culture experiments it was 3,000 times more active against the herpes simplex virus than it was against the host cell.[3]

● Low toxicity in normal cells
Because of its ultra-selectivity, ZOVIRAX has extremely low toxicity. A report on this selectivity describes ZOVIRAX as ".. a new class of antiviral agent that has extremely low toxicity for normal cells while having an inhibitory activity against HSV which is greater than that of any hitherto known compound."[3]

● An agent of promise
Wellcome take particular pride in introducing ZOVIRAX, a preparation which we believe heralds a new era in antiviral chemotherapy.

1. Collum, L M T *et al Brit. J. Ophthalmol.*, (1980), **64**, 766 **2.** *J. Antimicrob. Chemother.*, (1979), **5**, 431 **3.** *Proc Natl Acad Sci USA.*, (1977), **74**/12, 5716

PRESCRIBING INFORMATION **Presentation** Acyclovir 3 per cent w/w in a white soft paraffin base. **Uses** Treatment of herpes simplex keratitis. **Dosage and administration** A 1 cm ribbon of ointment should be placed inside the lower conjunctival sac five times a day at approximately four-hourly intervals. Treatment should continue for at least 3 days after healing is complete. **Contra-indications** Patients with a known hypersensitivity to acyclovir. **Warnings and adverse effects** For ophthalmic use only. Transient mild stinging immediately following administration occurs in a small proportion of patients. Superficial punctate keratopathy has been reported but has not resulted in patients being withdrawn from therapy, and healing has occurred without apparent sequelae. (PL 3/0150)

Further information is available on request. Wellcome Medical Division, The Wellcome Foundation Ltd., Crewe, Cheshire

NT ADVANCE
EATMENT
LEX INFECTIONS

NEW

ZOVIRAX* OPHTHALMIC OINTMENT

The effective, selective antiviral

* Trade Mark

Wellcome

for strabismus surgery synthetic absorbable

Coated VICRYL*

(polyglactin 910) sutures

- **Controlled Knot Placement**
- **Smooth passage through tissue**

The benefits of Coated VICRYL (Polyglactin 910) are of particular value when used in Strabismus surgery. The coating permits easy placement of the suture with minimal drag through muscle or scleral tissues. The suture will not lock prematurely on the knot. A square or reef knot can be eased into the correct position prior to it being locked securely with extra throws enabling accurate approximation to be achieved easily and consistently.

ETHICON

Ethicon Ltd., PO Box 408, Bankhead Avenue, Edinburgh EH11 4HE, Scotland.

Downs Surgical in Ophthalmology









The Downs Microbipolar Coagulator is suitable for all micro-surgical procedures, especially in ophthalmic surgery. The smooth linear control scale of the power source allows minimal tissue adhesion to the specially designed forceps. The design conforms to International Safety Standards making the unit both easy to use and totally safe.

Micra Diamond knives. Originally developed for precise cutting of the cornea in micro-ophthalmic procedures, have applications throughout microsurgery.

These revolutionary knives have fully retractable tips, completely protecting the diamond when not in use. The knives are available in six shapes and five different handles.

The diamond cutting edge is very hard, is unaffected by normal sterilisation methods and if damaged can normally be re-sharpened.

Our range of **Titanium Micra Ophthalmic** instruments has recently been updated. The forceps have finer tips. The needleholders and scissors have been redesigned and are now much finer. The plain forceps, tying forceps, needleholders and blade holders are now available with a special tungsten carbide surface on the jaws.

Titanium has the advantages of strength, lightness, low reflection under the microscope, corrosion resistance and is anti-magnetic.

The Maquet 1122 Operating Table System gives a very rigid ophthalmic table with electrically powered height adjustment and X-Y movement, ideal for microsurgery. The detachable top and transporter gives an extremely gentle method of patient transfer. The Maquet 1122 Table complements any microscope system.

For further details tick appropriate box(es), complete form and return to address below.

- ☐ Maquet 1122 Operating Table System
- ☐ Titanium Micra Ophthalmic instruments
- ☐ Downs Microbipolar Coagulator
- ☐ Diamond Knives

Name .....

Position .....

Address .....

.....

Telephone .....

Downs Surgical

Downs Surgical Ltd Church Path, Mitcham, Surrey, CR4 3UE, England. Telephone 01-648 6291

MOST ACCEPTABLE

Diamox Sustets – sustained release acetazolamide has a far longer duration of effect in glaucoma than any other treatment. Diamox Sustets provides smooth and predictable control of intra-ocular pressure – with significant reduction in the adverse effects associated with systemic therapies for this condition.[1]

Diamox Sustets, with a simple b.d. dosage is well accepted by patients.....



.....and physicians, alike.

"Fifty-eight percent of the patients could be expected to tolerate [Diamox Sustets] beyond six weeks.... This is greater than any of the other agents. ...it seems worthwhile to begin treatment with this drug at the dosage levels used in this study".[2]

Diamox* Sustets*

acetazolamide

THE SYSTEMIC TREATMENT FOR GLAUCOMA

INDICATIONS Glaucoma. **DOSAGE Adults:** One capsule at night and in the morning. **Contra-indications:** Idiopathic renal hyperchloraemic acidosis, Addison's disease or all types of suprarenal gland failure. Long-term administration in patients with chronic congestive angle-closure glaucoma. **Precautions:** The patient should be cautioned to report any unusual skin rash. Periodic blood cell counts are recommended. The transitory loss of hearing calls for immediate cessation of medication. **Side-effects:** Drowsiness, paraesthesia of extremities and face may occur. Diamox is a sulphonamide derivative and therefore some side-effects similar to those caused by sulphonamides have occasionally been reported. **Drug interactions:** Possible potentiation of the effects of folic acid antagonists, hypoglycaemics and oral anticoagulants may occur. **Package quantities:** Transparent orange capsules each containing 500mg. of acetazolamide and printed 'Lederle 4309' in bottles of 30, 100 and 500. **Basic N.H.S.** cost: £21.70 per 100. PL 0095/5074.

*Trademark. **References:** 1. Garner, L.L. et al. Amer. J. Ophthalmol. 1963, 55, 2, 323-327. 2. Lichter, P.R. et al. Amer. J. Ophthalmol. 1978, 85, 4, 495-502.

Lederle Laboratories. A division of Cyanamid of Great Britain Limited. Fareham Road, Gosport, Hampshire PO13 0AS. Tel. no. (0329) 236131.

Non-returnable

new from ALCON

OPULETS

true, single-dose, sterile eye drop system



Snap-off non-returnable cap

Minimal risk of contamination

Dose measurement simplified

Simplicity of application assured

Economical

Opulets from Alcon—a true single dose, sterile eye drop system. Each sterile unit contains sufficient solution for just one dose and the non-returnable cap makes disposal essential. The risk of contamination is minimized, dose measurement is simplified and ease of use is assured. Now available in packs of twenty: Chloramphenicol 0.5%, Cyclopentolate 1.0%, Fluorescein 1.0% Sodium Chloride 0.9%, Atropine 1.0%, and Benoxinate 0.4%. Future additions to the range will be made at regular intervals.

ALCON

a true solution for eyecare

Alcon Laboratories (U.K.) Limited
Boundary Way, Hemel Hempstead
Hertfordshire HP2 7UD, England



With significantly less effect on intra-ocular pressure

Eumovate Eye Drops have significantly less effect on intra-ocular pressure than hydrocortisone, betamethasone, prednisolone or dexamethasone eye drops.

'It is therefore of some significance that with clobetasone butyrate it has been possible to dissociate the adverse intra-ocular pressure effect from the advantageous anti-inflammatory effects, and thus we may well have a "safer" steroid for use in ophthalmology.'

Ramsell TG, Bartholomew RS, Walker SR. Br J Ophthalmol 1980; 64: 43-5.

Eumovate Eye Drops
(clobetasone butyrate)

Eumovate-N Eye Drops
(clobetasone butyrate and neomycin)

Prescribing information

Indications
Eumovate Eye Drops are indicated for the treatment of non-infected inflammatory conditions of the eye Eumovate-N Eye Drops are indicated for inflammatory conditions of the eye where secondary bacterial infection is likely to occur

Dosage and administration
The usual dosage is one to two drops four times a day for severe inflammatory conditions one or two drops should be instilled into the eye every one or two hours until control is achieved, when the frequency may be reduced

Contra-indications
Viral, fungal, tuberculous or purulent conditions of the eye, hypersensitivity to any component of the preparation Use is contra-indicated if glaucoma is present Eumovate Drops and Eumovate N Drops contain benzalkonium chloride as a preservative and therefore should not be used to treat patients who wear soft contact lenses.

Precautions
Although Eumovate Eye Drops have been shown to have little effect on intra ocular pressure in most patients, those receiving long term treatment should have their intra ocular pressure monitored frequently.
Cataract is reported to have occurred after unduly prolonged treatment with some topical corticosteroids and in those diseases which cause thinning of the cornea, perforation has been known to occur
In general, topical steroids should not be used extensively in pregnancy, i e , in large amounts or for prolonged periods

Side effects
Rises in intra-ocular pressure have been reported in susceptible patients but these are generally much less than with other corticosteroid eye preparations, including hydrocortisone

Product Licence numbers

Eumovate Drops	4/0260
Eumovate-N Drops	4/0276

Presentation		Basic NHS cost (exclusive of VAT) £
Eumovate Eye Drops (in plastic dropper bottles)	5ml	1·80
	10ml	3·33
Eumovate N Eye Drops (in plastic dropper bottles)	5ml	1·80
	10ml	3·33

Glaxo

Further information on Eumovate Eye Drops and Eumovate N Eye Drops is available from Glaxo Laboratories Limited Greenford, Middlesex UB6 0HE
Eumovate is a Glaxo trade mark

THE ORIGINAL SINSKEY POSTERIOR CHAMBER LENS

IOLAB Model 103 Series
designed in cooperation with
Robert M. Sinskey, M.D.

IOLAB "Sinskey" style lenses

- Capsular bag and/or ciliary sulcus fixation.
- Loop configuration designed for flexibility.
- Posterior blue loops for visualization.
- 10° loop angle to place optic away from iris.
- Rounded loop tips.



- Compressible Prolene* loop suspension system.
- 0.4mm positioning holes.

**Trademark of ETHICON, Inc.*

- IODENTIFICATION™ clearly marks each lens with its dioptric power.
- AcuMold™ is a unique system of injection molding for IOLs.
- Videotapes, Course details, and Literature available from:–

IOLAB, 110-112 High Street,
Maidenhead, Berkshire
SL6 1QQ
Telephone: (0628) 74811
Telex: 849400 CODMAN

EUROPE

CONJUNCTIVITIS? BLEPHARITIS?

Ocular infections demand SNO®PHENICOL

Sno®phenicol contains Chloramphenicol Ph.Eur. 0.5%

Chloramphenicol
- is a broad spectrum antibiotic
- is well proven in ophthalmic use
- is effective against a wide range of Gram positive and Gram negative organisms
- is well absorbed by the cornea
- is indicated for – **conjunctivitis, blepharitis** and other inflammatory conditions of infectious origin

Sno®phenicol contains Polyvinyl alcohol

Polyvinyl alcohol
- increases the viscosity of the solution
- increases the contact time of solutions with the cornea
- increases patient comfort
- is extensively used in contact lens solutions and eye drops

Sno®phenicol is packed in a plastic bottle

The plastic bottle
- ensures easy instillation
- prevents breakages

DOSAGE AND ADMINISTRATION
Adult: 1 or more drops as required. Children: 1 drop as required.

CONTRA-INDICATIONS, WARNINGS, etc.
Treatment with chloramphenicol should be discontinued immediately if there are signs of allergy (usually localised drug rash). This may be treated by topical hydrocortisone and/or antihistamines by mouth. This product is not intended as a long term treatment for dry eye syndromes.

PRODUCT LICENCE NUMBER
0033/0076

SMITH & NEPHEW
Pharmaceuticals Ltd
Bampton Road, Harold Hill, Romford, Essex, RM3 8SL

Improve on your most frequent choice



This blue nozzle† makes it easier to apply

Chloromycetin

chloramphenicol eye ointment BP

Ophthalmic ointment

Further information (including data sheet) is available on request:
Parke, Davis and Company, Usk Road, Pontypool, Gwent NP4 0YH. Tel: Pontypool (04955) 2468.

Chloromycetin and the device showing a tube having a blue nozzle are the trade marks of Parke, Davis and Company for ophthalmic preparations containing chloramphenicol. † Blue Nozzle patent no. 8018334 pending.

P456-UK-May 81

PARKE-DAVIS

Cover every move with MINIMS™

The range of single use eye drops with the following advantages

includes 19 different agents* for Mydriasis, Cyclopegia, Miosis, Local Anaesthesia, Staining, Antibacterial action and Irrigation.

when applicable more than one strength is available.

new additions are regularly introduced in order to meet the everchanging demands of ophthalmology.

each unit is individually overwrapped to ensure sterility at the time of use.

a comprehensive guide to the range is available from

SMITH & NEPHEW Pharmaceuticals Ltd
Bampton Road, Harold Hill, Romford, Essex, RM3 8SL
Tel: Ingrebourne (04023) 49333

*The current Minims range comprises the following:-
Atropine Sulfate Ph.Eur. 1.0%, Cyclopentolate Hydrochloride BP 0.5 & 1.0%, Homatropine Hydrobromide Ph.Eur. 2%, Hyoscine Hydrobromide Ph.Eur. 0.2%, Phenylephrine Hydrochloride BP 10%, Tropicamide BP 0.5 & 1.0%, Pilocarpine Nitrate Ph.Eur. 1.0, 2.0 & 4.0%, Amethocaine Hydrochloride Ph.Eur. 0.5 & 1.0%, Benoxinate Hydrochloride U.S.P. 0.4%, Lignocaine Hydrochloride Ph.Eur. 4.0% + Fluorescein Sodium BP 0.25%, Fluorescein Sodium BP 1.0 & 2.0%, Rose Bengal 1.0%, Chloramphenicol Ph.Eur. 0.5%, Neomycin Sulfate Ph.Eur. 0.5%, Sulfacetamide Sodium BP 10.0%, Gentamicin 0.3%, Prednisolone Sodium Phosphate BP 0.5%, Sodium Chloride Ph.Eur. 0.9%, Castor Oil Ph.Eur.

Reaches the parts...

Before a steroid can reach the inflamed anterior segment of the eye, it must penetrate the three barriers of the cornea: the epithelium, endothelium, and the stroma.

Maxidex is dexamethasone alcohol 0.1%. The free base is soluble in fat and water, allowing Maxidex to pass quickly through the corneal barriers to the site of inflammation.

The Isopto vehicle in Maxidex resists tear wash-out and extends corneal contact time of the compound; thus increasing the amount of penetrating dexamethasone, enhancing the anti-inflammatory effect.



MAXIDEX®

Ophthalmic suspension
Dexamethasone 0.1%

fast relief from inflammation



Prescribing information

Presentation Dexamethasone 0.1% in a vehicle containing 0.5% hydroxypropyl methylcellulose, hypromellose. A sterile, isotonic ophthalmic suspension. **Clinical Uses** Maxidex is indicated in the treatment of certain inflammatory conditions of the anterior segment: Acute and chronic anterior uveitis; iritis; iridocyclitis; cyclitis; herpes zoster ophthalmicus. External diseases not specific (superficial keratitis, Phlyctenular keratoconjunctivitis, vernal conjunctivitis, allergic, catarrhal and non purulent conjunctivitis). Recurrent marginal ulceration of toxic or allergic aetiology. Thermal or chemical burns. Post operatively to reduce inflammatory reactions. **Dosage and Administration** For severe to acute inflammations 1 or 2 drops to be instilled into the eye every 30-60 mins. for at least 3-4 days or until a satisfactory response is made. Then every 2 to 3 hours for one to two weeks. If a favourable response is not obtained in 3-4 days subconjunctival or systemic therapy should be instituted. **Contra-Indications** Herpes simplex and other viral diseases of the cornea and conjunctiva. Fungal disease, tuberculosis and acute purulent untreated infections. **Warnings** Extended use of topical steroids may increase intraocular pressure which should be checked frequently. In those diseases causing thinning of the cornea, perforation has been known to occur with the use of topical steroids. If the inflammation does not respond within a reasonable period other forms of therapy should be instituted. If any reaction indicating sensitivity is observed, discontinue use. In cases of bacterial infections, concomitant use of antibiotics or chemotherapeutics is mandatory. Intensive or prolonged topical corticosteroid therapy is a possible factor in the formation of posterior subcapsular cataracts. **Pregnancy Warning** Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their use in pregnancy has not been absolutely established; therefore it is advisable not to use this product for long term treatment of pregnant patients. **Pharmaceutical Precautions** Maxidex should be stored in a cool place away from direct sunlight. Keep the container tightly closed. The contents should be discarded one month after opening. Shake well before using. **Legal Category** P. U.S.A. POM **Package Quantity** 5 ml and 15 ml containers. **Further Information** Maxidex eye drops are contained in an unbreakable semi-rigid plastic dropper bottle with a screw on cap, containing 5 ml or 15 ml of the preparation. This container bears the label and is itself in a red capped plastic outer. Maxidex is a highly penetrating form of dexamethasone, a 0.1% micronised suspension especially formulated to provide maximum corneal absorption. **Product Licence** 0649-5914. **Product Licence Holder** Alcon Laboratories (U.K.) Limited, Imperial Way, Watford, Hertfordshire. Additional material on available on request.

Alcon Laboratories (UK) Limited, Imperial Way, Watford, Hertfordshire, WD2 4YR. Telephone: Watford 46133. Telex: 923709. Cable: Alcon, Watford.

Alcon

Builds tear film back to normal thickness

Diminishes stickiness, blurring and crusting

Long duration of activity, 90 minutes

Long break-up time with low viscosity

Convenient and comforting

TEARS Naturale

an excellent choice in dry eye therapy

Alcon

Further information is available from Alcon Laboratories (U.K.) Ltd., Imperial Way, Watford, Herts. WD2 4YR.
Telephone: Watford 46133. Telex: 923709.
Cable: Alcon, Watford.

P.L. 0649/0031.

PILOCARPINE?



Switch to 'Timoptol'. A positive answer to glaucoma.

There's no doubt that 'Timoptol' has positive advantages over pilocarpine in the treatment of glaucoma, and particularly in established patients. 'Timoptol' offers superior control of intra-ocular pressure through the 24 hours, and avoids the disturbing side effects of pilocarpine, such as pupil constriction.

The single drop twice-daily dose of 'Timoptol' (0.25% or 0.5%), encourages much greater patient compliance. It's time you let your established glaucoma patients see things your way.

Ophthalmic Solution

Timoptol®

Timolol maleate, MSD

For prescribing information, please see overleaf

MSD MERCK SHARP & DOHME

Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, EN11 9BU

83.TOT.82.GB.8365.J



full field lenses

FUL-VUE lenses – looking better, seeing better

Here is visual evidence of how FUL-VUE lenses improve off-axis acuity. See for yourself: the rotating eye sees more clearly through the FUL-VUE lens than it can through a commonly used full-field lens. And FUL-VUE lenses are more attractive than lenticular style lenses too.

FUL-VUE lenses

The cataract lens system with a demonstrable difference



Further information is available on request.

British American Optical Company, Radlett Road, Watford, Herts WD2 4LJ. Telephone: Watford (0923) 33522

FML, the potent steroid, that's gentle on pressure.

FML (FLUOROMETHOLONE) LIQUIFILM STERILE OPHTHALMIC SUSPENSION. Abbreviated Prescribing Information. **Uses**: Topical ophthalmic suspension for steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. **Dosage and administration**: 1 to 2 drops instilled into the conjunctival sac two to four times daily. **Contra-indications, warnings, etc**: *Contra-indications*: Acute superficial Herpes simplex keratitis. Fungal diseases of ocular structures. Vaccinia, varicella and most other viral diseases of the cornea and conjunctiva. Tuberculosis of the eye. *Warnings*: Steroid medication in the treatment of Herpes simplex keratitis (involving the stroma) requires great caution: frequent slit-lamp microscopy is mandatory. Prolonged use may result in glaucoma, damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, or may aid in the establishment of secondary ocular infections from fungi or viruses liberated from ocular tissue. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with use of topical steroids. This preparation contains benzalkonium chloride and should be used with caution in association with hydrophilic contact lenses. *Precautions*: As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid applications, fungus invasion must be suspected in any persistent corneal ulceration where a steroid has been used or is in use. *Adverse reactions*: Glaucoma with optic nerve damage, visual acuity or field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens liberated from ocular tissues, perforation of the globe. Local side-effects of steroid therapy, i.e. skin atrophy, striae and telangiectasia, are especially likely to affect facial skin. Legal Category: POM. Basic NHS cost: £1.62 for 5ml, £2.57 for 10ml. Product Licence No: 0426/0028. References: 1. Kupferman and Leibowitz, Arch. Opthal., Vol 93 1011-3, Oct 1975. 2. Fairbairn and Thorson, Arch. Ophthal., Vol 86, 138-140, Aug 1971. 3. Mindel et al., Arch. Ophthal., Vol 98, 1577-8, Sept 1980. Further information is available from the Company. AL/1.

ALLERGAN

Allergan Limited, Fennels Lodge, St. Peters Close, Loudwater, High Wycombe, Bucks. HP11 1JT. Tel: Bourne End (06285) 27778

FML has comparable efficacy to dexamethasone[1] and prednisolone[1,2] with less tendency to raise IOP than prednisolone,[2] dexamethasone[3] or betamethasone.[2]

FML

INTRACAPSULAR AND EXTRACAPSULAR POSTERIOR CHAMBER LENS



IOLAB Model 103S
designed in cooperation with
Sanford L. Severin, M.D.

IOLAB MODEL 103S

Posterior chamber placement of optic following intracapsular surgery.

Also suitable for extracapsular surgery.

Stable alternative to pre-pupillary lens following intracapsular surgery.

Easier insertion of the lens behind the iris.

Posterior blue loops for visualization.



- IODENTIFICATION™ clearly marks each lens with its dioptric power.
- Iris plane support for posterior chamber optic.

- AcuMold™ is a unique system of injection molding for IOLs.
- Choice of suture or clip fixation.
- Videotapes, Course details, and Literature available from:–

IOLAB, 110-112 High Street,
Maidenhead, Berkshire
SL6 1QQ
Telephone: (0628) 74811
Telex: 849400 CODMAN

EUROPE

Published by British Medical Association, Tavistock Square, London WC1H 9JR.
Typesetting by Bedford Typesetters Ltd., Bedford, England. Printed by Paramount Printing Co. Ltd., Hong Kong